Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection

NCT04019717 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C
Hepatitis C, Chronic
Chronic Hepatitis C
Hepatitis C Virus Infection
HCV Infection

Interventions

DRUG: AT-527
DRUG: Daclatasvir

Sponsor

Atea Pharmaceuticals, Inc.